Teleflex signs MoU with Fortis Hospitals in India to create a UroLiftTM Center of Education
Teleflex announced that 500 patients have been treated with its UroLift™ System in India and Fortis Hospitals is the first hospital to treat about 100 BPH patients with the UroLift™ System.
The UroLift™ System uses a minimally invasive approach to treating Benign Prostatic Hyperplasia (BPH). BPH is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life1. The UroLift™ System is the only leading BPH procedure that does not require heating, cutting, removal, or destruction of prostate tissue 2,3. The UroLift™ System provides rapid symptom relief 2 and preserves sexual function 5*. Typically, no catheter is required after the treatment 2,4.
'At Teleflex, we believe that education is the foundation of progress in healthcare. Our collaboration with Fortis Hospitals will empower medical professionals with advanced knowledge and hands-on training, ultimately improving patient care,' said Arun Kaushik, Managing Director, South Asia, Teleflex.
Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare Limited stated, 'The healthcare landscape continues to evolve, and more minimally invasive therapies continue to emerge. At Fortis, we always strive to offer superior technologies to our patients. This educational initiative in association with Teleflex is another testament to our commitment to quality patient care.'
Dr. Mohan Keshavamurthy, Principal Director – Renal Sciences, Fortis Hospitals, Bengaluru, said, 'Through this collaboration, we are committed to helping Urologists acquire requisite skill to optimise individualised treatment solutions such as UROLIFT for patients requiring Endoscopic surgical solutions for BPH and enhancing outcomes thereof. The programme is designed to provide a comprehensive training program to Urologists to ensure careful selection and safe delivery of the UroLift System to patients in their practice.'
These training programs for the UroLift™ System will be conducted at Fortis Hospitals, Bannerghatta Road, Bengaluru.
About the UroLift™ System
The UroLift™ System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 50 years and above in India. In India, prostatic urethral lift like UroLift is an optional therapy and shall be offered as an alternative to patients presenting with moderate-to-severe LUTS who failed to respond to medical management and who are not tolerant or compliant to medical management (GR optional). The UroLift permanent implants, delivered during the procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. 2,3 The UroLift™ System can be used to treat a broad spectrum of anatomies, including obstructive median lobe. 7 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*3,5,6 Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence 2. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines as well as an optional procedure for BPH management in Urological Society of India guidelines 9. More than 500,000 men have been treated with the UroLift™ System in select markets worldwide.8 Learn more at UroLift.com. Rx only.
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in the world of healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rusch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.
References:
1. Speakman et al. 2014 BJUI International
2. Roehrborn, J Urology 2013
3. AUA BPH Guidelines 2003, 2020
4. Shore, Can J Urol 2014
5. Roehrborn, Can J Urol 2017
6. McVary, J Sex Med 2016
7. Rukstalis, Prostate Cancer and Prostatic Dis 2018
8. Management estimate based on product sales and average units per procedure
9. Urological Society of India BPH Guidelines, 2019
*No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by HT Syndication. ANI will not be responsible in any way for the content of the same)
This story is auto-generated from a syndicated feed. ThePrint holds no responsibility for its content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
7 hours ago
- Business Standard
Veeda Lifesciences announces partnership with Mango Sciences to bring AI innovation in clinical trials services
PRNewswire Ahmedabad (Gujarat) [India], July 8: Veeda Lifesciences, a global contract research organization (CRO), has announced an investment in Mango Sciences, a Boston-based healthcare AI and data company. Through this investment, Veeda intends to leverage AI capabilities to enhance the speed, efficiency, and quality of Clinical Trials services across its expanded global network, enabling more diverse, efficient recruitment and globally representative patient selection. By leveraging Mango Sciences' AI-powered Querent™ platform, Veeda will effectively use technology to automate patient identification with precision and expand its reach across Europe. "Our partnership will transform Veeda into an AI-driven oncology drug development organization, meeting the growing demand for diversity in clinical trials, which is in line with the expectations of regulators and pharmaceutical companies. We will be one of only a few CROs focused in Oncology with access to this proprietary technology," said Dr. Mahesh Bhalgat, Group CEO and Managing Director, Veeda Clinical Research Limited. This partnership promotes Veeda's objectives of investing in technology modernization and digital transformation to enhance operational efficiency and quality assurance across its clinical research operations. By deploying the AI-powered Querent™ platform, Veeda will streamline processes, improve data management capabilities, and ensure higher quality standards through broader representation of non-Caucasian populations. This will enhance clinical trial efficiency through advanced data analytics--improving patient matching, trial design, and monitoring while reducing costs and timelines. Dr. Mohit Misra, Founder & CEO of Mango Sciences, added, "We are integrating Large Language Models (LLMs) and Generative-AI into Querent™ to drive operational efficiencies and improve real-world evidence, ultimately identifying the right drug for the right patient." Veeda has strengthened its position as a tech-enabled, AI-driven CRO through strategic investments and the acquisition of Health Data Specialists (Heads) previously. This provides Veeda with access to oncology cohorts in India and Europe and with exclusive access to eligible patient pools. This supports Veeda's aim to maintain a competitive edge in the CRO sector while delivering services to pharmaceutical and biopharmaceutical clients globally. About Veeda Lifesciences: Veeda Lifesciences (Veeda Clinical Research Limited) platform provides a comprehensive portfolio of services across various stages of the drug development value chain to support small and medium biotech and pharmaceutical companies with capabilities ranging from non-clinical and pre-clinical development to clinical pharmacology and clinical trials across different modalities. Visit: About Mango Sciences: Mango Sciences is a healthcare data and AI technology company dedicated to transforming patient care through advanced data analytics and solutions. Founded by industry veterans with extensive experience in healthcare, life sciences, and data analytics, Mango Sciences is driven by a passion for improving patient representation and access to comprehensive healthcare. Visit: Disclaimer: Veeda Clinical Research Limited (the "Company") is proposing, subject to receipt of requisite approvals, market conditions and other considerations, a public issue of its equity shares soon and is in the process of filing a draft red herring prospectus with the Securities and Exchange Board of India. This document is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and will contain detailed information about the Company and management, as well as financial statements. The Company does not intend to register any part of the offering in the United States.
The Wire
7 hours ago
- The Wire
Veeda Lifesciences announces partnership with Mango Sciences to bring AI innovation in clinical trials services
AHMEDABAD, India, July 8, 2025 /PRNewswire/ -- Veeda Lifesciences, a global contract research organization (CRO), has announced an investment in Mango Sciences, a Boston-based healthcare AI and data company. Through this investment, Veeda intends to leverage AI capabilities to enhance the speed, efficiency, and quality of Clinical Trials services across its expanded global network, enabling more diverse, efficient recruitment and globally representative patient selection. By leveraging Mango Sciences' AI-powered Querent™ platform, Veeda will effectively use technology to automate patient identification with precision and expand its reach across Europe. "Our partnership will transform Veeda into an AI-driven oncology drug development organization, meeting the growing demand for diversity in clinical trials, which is in line with the expectations of regulators and pharmaceutical companies. We will be one of only a few CROs focused in Oncology with access to this proprietary technology," said Dr. Mahesh Bhalgat, Group CEO and Managing Director, Veeda Clinical Research Limited. This partnership promotes Veeda's objectives of investing in technology modernization and digital transformation to enhance operational efficiency and quality assurance across its clinical research operations. By deploying the AI-powered Querent™ platform, Veeda will streamline processes, improve data management capabilities, and ensure higher quality standards through broader representation of non-Caucasian populations. This will enhance clinical trial efficiency through advanced data analytics—improving patient matching, trial design, and monitoring while reducing costs and timelines. Dr. Mohit Misra, Founder & CEO of Mango Sciences, added, "We are integrating Large Language Models (LLMs) and Generative-AI into Querent™ to drive operational efficiencies and improve real-world evidence, ultimately identifying the right drug for the right patient." Veeda has strengthened its position as a tech-enabled, AI-driven CRO through strategic investments and the acquisition of Health Data Specialists (Heads) previously. This provides Veeda with access to oncology cohorts in India and Europe and with exclusive access to eligible patient pools. This supports Veeda's aim to maintain a competitive edge in the CRO sector while delivering services to pharmaceutical and biopharmaceutical clients globally. About Veeda Lifesciences: Veeda Lifesciences (Veeda Clinical Research Limited) platform provides a comprehensive portfolio of services across various stages of the drug development value chain to support small and medium biotech and pharmaceutical companies with capabilities ranging from non-clinical and pre-clinical development to clinical pharmacology and clinical trials across different modalities. Visit: About Mango Sciences: Mango Sciences is a healthcare data and AI technology company dedicated to transforming patient care through advanced data analytics and solutions. Founded by industry veterans with extensive experience in healthcare, life sciences, and data analytics, Mango Sciences is driven by a passion for improving patient representation and access to comprehensive healthcare. Visit: Disclaimer: Veeda Clinical Research Limited (the "Company") is proposing, subject to receipt of requisite approvals, market conditions and other considerations, a public issue of its equity shares soon and is in the process of filing a draft red herring prospectus with the Securities and Exchange Board of India. This document is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and will contain detailed information about the Company and management, as well as financial statements. The Company does not intend to register any part of the offering in the United States. Logo: (Disclaimer: The above press release comes to you under an arrangement with PRNewswire and PTI takes no editorial responsibility for the same.).
India Gazette
3 days ago
- India Gazette
Teleflex signs MoU with Fortis Hospitals in India to create a UroLift Center of Education
HT Syndication New Delhi [India], July 5: Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has signed a Memorandum of Understanding with Fortis Hospitals Bengaluru to create the UroLift Center of Education in India. Teleflex announced that 500 patients have been treated with its UroLift System in India and Fortis Hospitals is the first hospital to treat about 100 BPH patients with the UroLift System. The UroLift System uses a minimally invasive approach to treating Benign Prostatic Hyperplasia (BPH). BPH is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life. The UroLift System is the only leading BPH procedure that does not require heating, cutting, removal, or destruction of prostate tissue. The UroLift System provides rapid symptom relief and preserves sexual function. Typically, no catheter is required after the treatment. 'At Teleflex, we believe that education is the foundation of progress in healthcare. Our collaboration with Fortis Hospitals will empower medical professionals with advanced knowledge and hands-on training, ultimately improving patient care,' said Arun Kaushik, Managing Director, South Asia, Teleflex. Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare Limited stated, 'The healthcare landscape continues to evolve, and more minimally invasive therapies continue to emerge. At Fortis, we always strive to offer superior technologies to our patients. This educational initiative in association with Teleflex is another testament to our commitment to quality patient care.' Dr. Mohan Keshavamurthy, Principal Director - Renal Sciences, Fortis Hospitals, Bengaluru, said, 'Through this collaboration, we are committed to helping Urologists acquire requisite skill to optimise individualised treatment solutions such as UROLIFT for patients requiring Endoscopic surgical solutions for BPH and enhancing outcomes thereof. The programme is designed to provide a comprehensive training program to Urologists to ensure careful selection and safe delivery of the UroLift System to patients in their practice.' These training programs for the UroLift System will be conducted at Fortis Hospitals, Bannerghatta Road, Bengaluru. About the UroLift System The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 50 years and above in India. In India, prostatic urethral lift like UroLift is an optional therapy and shall be offered as an alternative to patients presenting with moderate-to-severe LUTS who failed to respond to medical management and who are not tolerant or compliant to medical management (GR optional). The UroLift permanent implants, delivered during the procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift System can be used to treat a broad spectrum of anatomies, including obstructive median lobe. It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction. Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines as well as an optional procedure for BPH management in Urological Society of India guidelines. More than 500,000 men have been treated with the UroLift System in select markets worldwide. Learn more at Rx only. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in the world of healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rusch, UroLift and Weck - trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit References: 1. Speakman et al. 2014 BJUI International 2. Roehrborn, J Urology 2013 3. AUA BPH Guidelines 2003, 2020 4. Shore, Can J Urol 2014 5. Roehrborn, Can J Urol 2017 6. McVary, J Sex Med 2016 7. Rukstalis, Prostate Cancer and Prostatic Dis 2018 8. Management estimate based on product sales and average units per procedure 9. Urological Society of India BPH Guidelines, 2019 *No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study. (ADVERTORIAL DISCLAIMER: The above press release has been provided by HT Syndication. ANI will not be responsible in any way for the content of the same)
